Developments in Cancer Treatments, Market Dynamics, Patient Access and Value: Global Oncology Trend Report 2015
In this report, we share our updated perspective on the clinical landscape and what lies ahead; the dynamics of the market for oncology-related pharmaceuticals; and the current state of patient access to medicines and value considerations.
The pace of change in cancer care is accelerating. A cluster of innovative treatments, often combined with other new or existing medicines, and frequently associated with biomarkers, are emerging from the research and development pipeline. Many are for tumor types associated with low survival rates and where patients have limited options. The landscape is shifting rapidly, bringing new complexity to oncologists, payers and governments who all look to provide appropriate care to patients while ensuring the sustainability of healthcare systems. Earlier diagnosis, longer treatment duration and increased effectiveness of drug therapies are contributing to rising levels of spending on medicines for cancer care.
News & Media Coverage
- Press Release: IMS Health Finds Global Cancer Drug Spending Crossed $100 Billion Threshold in 2014
- Fortune: Cancer drug spending hit $100 billion in 2014. Here's why it'll soon be much higher
- International Business Times: Cancer Drug Costs Hit All-Time High: The $100 Billion Disease
- Reuters: Global cancer drug spending hits $100 billion in 2014: IMS Health
- US News & World Report: Global Cancer Spending Reaches $100B
- CNBC: Cancer drug spending tops $100 billion, up 10% in a year
Below, IMS Institute Executive Director Murray Aitken discusses key findings in this report. Click here to view additional videos from this report.
Survival Rates have Steadily Improved Over the Past 20 Years
- Earlier diagnosis, longer treatment duration and increased effectiveness of drug therapies are contributing to rising levels of spending on medicines for cancer care
- In most instances, five-year survival rates have risen through continuous and small improvements in detection and treatment – including refinements with existing treatments and gains from new treatment options
Validated pathways reduce clinical trial risk, facilitating “fast follower” strategies with rising competitive intensity
- An analysis of pipeline agents for five specific mechanisms of action shows 100 phase II and phase III trials targeting eleven key tumors. These investigations include both NMEs and new indications for drugs currently on the market.
- Many molecules will fail to reach approval; however, the substantial number of NMEs in the classes with proven activity, e.g., VEGF and PD-1/PDL-1 inhibitors, suggests that direct competition can be expected to increase in multiple indications. This competition may lessen as products within a given class show differing levels of effectiveness in different cancers.
Global oncology spending reaches $100 billion in 2014
- The report found that total global spending on oncology medicines – including therapeutic treatments and supportive care – reached the $100 billion threshold in 2014, even as the share of total medicine spending of oncologics increased only modestly
- Growth in global spending on cancer drugs – measured using ex-manufacturer prices and not reflecting off-invoice discounts, rebates or patient access programs – increased at a compound annual growth rate (CAGR) of 6.5 percent on a constant-dollar basis during the past five years
Assessment of value for oncology products is becoming more complex as most products have multiple indications
- By 2020, most oncology drugs will carry multiple indications, reflecting developers’pursuit of genetic targets across multiple tumors, and the rise of immuno- oncologics,which may have more than six indications
- Of 88 cancer drugs marketed in 2014, 40 were for single indications and 48 for multiple indications
The IMS Institute for Healthcare Informatics grants permission to use and reference this information, providing the IMS Institute report name and copyright information are clearly acknowledged. Exhibits may not be altered in any way.
- U.S. 5 Year Relative Survival (All Ages, Races, Gender)
- Pipeline by Number of Targeted Agents and Selected Pathways
To save the exhibits to your hard drive, right mouse click and select "Save Target As" or "Save Link As."
Note: All third party trademarks contained herein are the property of their respective owners and their use herein is for informational purposes and does not imply sponsorship or endorsement of their products or services.
Please fill out the form below to request the IMS Institute Developments in Cancer Treatments, Market Dynamics, Patient Access and Value: Global Oncology Trend Report 2015 report:
The report is being downloaded. Thank you for your interest.